Bristol-Myers vet Douglas Manion bids Big Pharma farewell, takes the helm at Yale spinout Kleo
A 12-year veteran of Bristol-Myers Squibb’s R&D group is joining the migration of research execs out of Big Pharma and into up-and-coming biotech.
Douglas Manion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.